CitationClemente S. Stereotactic body radiation therapy treatment for prostate cancer: From setup to delivery strategies. Radiol Open J. 2016; 1(2): 39-41.
No abstract
To assess the loco regional response and toxicity of patients to concurrent chemo-radiation with 6 fractions/week using Intensity Modulated Radiotherapy in locally advanced head and neck cancers. (oropharynx and hypopharynx). Materials and Methods: 20 patients with Stage III and stage IV, squamous cell carcinoma of Head and neck were enrolled. Target Volume Delinetion was done in accordence with Danish Head and Neck cancer group (DAHANCA) contouring guidelines. Differential radiation dose of 70 Gy, 63Gy and 56 Gy in 35 fractions using IMRT, delivered to GTV, CTV1 and CTV2 with weekly cisplatin with weekly assessment of response and toxicity. Results: The median age of the patients was 54 years ranging from 40 to 65 years. 14 and 6 patients had Hypopharyngeal and Oropharyngeal malignancy of squamous cell origin. 95% of patients received 70 Gy in 35 fractions with 4 cycles of concurrent Cisplatin. 18 patients completed treatemnt within 45 days of OTT. 16 patients had complete response and 4 had partial response. Grade I, II dermatitis was observed in 70% and 30% of patients, respectively. 5 patienst developed Grade 2 and 1 patinet developed grade 3 leucopenia. 2 patients had weight loss of more than 10%. 85% oforopharyngeal cancers and 67% of hypopharyngeal cancers showed complete response. Nodal response was 100% complete in N1 & N2a, 92% and 0% in N2b and N3 lesions respicyively. TNM stage group wise the complete response rates were 100% in stage III, 92% & 0% IVA & IVB. Conclusion: Accelerated fractionation with IMRT and concurrent chemotherapy is a feasible in locoregionally adanced head and neck cancers with acceptable toxicities and good locoregional response rates.
Purpose: Despite Intensity Modulated Radiotherapy being the standard of care for most sites, 3D conformal radiotherapy (3DCRT) is still more widely used in esophageal cancers. This study compares dosimetric results of volumetric modulated arc therapy (RA) with that of 3DCRT and evaluates early clinical results of the patients treated with RA and chemotherapy. Materials and Methods: Evaluation of clinical outcomes in 10 patients treated definitively with RA and concurrent chemotherapy for esophageal cancer were included in the study. These patients were retrospectively planned with 3DCRT using antero-posterior portals till 3960cGy followed by obliques to a total dose of 5940cGy. The dose and target in each phase were kept same in both the plans. Dosimetric parameters were compared between the two plans using paired T-test or a Wilcoxon sign-rank based tests of normality on data distribution. Results: With a minimum follow-up of 4 months, all the patients tolerated the treatment without grade IV toxicities and treatment interruptions. 7 patients had a complete response and 3 had a partial response of which one patient underwent surgery and is disease free. RA resulted in higher conformity to the target compared to 3DCRT (mean conformity index 1.1 vs.1.8 respectively (p=0.002). RA plans significantly spared lung V15 (32% vs. 40.2%, p=0.003), V20 (22.7% vs. 29.7%, p=0.003), mean lung dose (13.8Gy vs.17.1Gy, p=0.003), heart V30 (46.8%vs.55.2% p=0.002), mean heart dose (24.3Gy vs.28.1Gy, p=0.003), and spinal cord maximum dose (44Gy vs.46.9Gy, p=0.002). The mean V5 and V10 values were similar with either technique. Conclusion: Irrespective of site of involvement, the RA resulted in better conformity and better sparing of heart, spinal cord and lungs beyond 15Gy. The dosimetric advantage gained with RA may become clinically relevant in reducing cardio-pulmonary complications especially in multimodality setting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.